naa a22 4500 510780024 CHVBK 20180411083243.0 cr unu---uuuuu 180411e20130401xx s 000 0 eng 10.1007/s11892-012-0362-8 doi (NATIONALLICENCE)springer-10.1007/s11892-012-0362-8 Omega-3 and Omega-6 Fatty Acids and Type 2 Diabetes [Elektronische Daten] [Charlotte Jeppesen, Katja Schiller, Matthias Schulze] Polyunsaturated fatty acids are of particular interest in the nutritional therapy for diabetes, given their potential role in several pathophysiological processes related to cardiovascular disease. Both omega-3 and omega-6 fatty acids are beneficial for improving lipid profiles in healthy individuals and among type 2 diabetic patients: Supplementation with omega-3 fatty acids lowers triglycerides and VLDL-cholesterol. However, they might also increase LDL-cholesterol. Omega-3 fatty acids are, from the latest evidence, not related to mortality and cardiovascular disease. Similarly, glucose control and hypertension, as well as risk of microvascular complications, seem unaffected by omega-3 supplementation. Most studies involved mainly patients with type 2 diabetes, and future research needs to focus on the type 1 diabetic patient. Also, the role of omega-6 fatty acids remains largely unknown. Springer Science+Business Media New York, 2013 Type 2 diabetes nationallicence Omega-3 fatty acids nationallicence Omega-6 fatty acids nationallicence Cardiovascular disease nationallicence Mortality nationallicence Microvascular complications nationallicence Intermediate outcomes nationallicence FA : fatty acids nationallicence EPA : eicosapentaenoic acid nationallicence DHA : docosahexaenoic acid nationallicence ALA : α- linoleic acid nationallicence PUFA : polyunsaturated fatty acids nationallicence T1D : type 1 diabetes nationallicence T2DM : type 2 diabetes nationallicence CVD : cardiovascular disease nationallicence MI : Myocardial infarction nationallicence CHD : coronary heart disease nationallicence TIA : transient ischemic attack nationallicence DN : Diabetic nephropathy nationallicence GFR : glomerular filtration rate nationallicence LDL : low density lipoprotein nationallicence VLDL : very low density lipoprotein nationallicence HDL : high density lipoprotein nationallicence IMT : Carotid intima-media thickness nationallicence ESRD : End-stage renal disease nationallicence UPE : urinary protein excretion nationallicence Jeppesen Charlotte Department of Molecular Epidemiology, German Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany aut Schiller Katja Department of Molecular Epidemiology, German Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany aut Schulze Matthias Department of Molecular Epidemiology, German Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany aut Current Diabetes Reports Current Science Inc. 13/2(2013-04-01), 279-288 1534-4827 13:2<279 2013 13 11892 https://doi.org/10.1007/s11892-012-0362-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-012-0362-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jeppesen Charlotte Department of Molecular Epidemiology, German Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany aut NATIONALLICENCE 700 1- Schiller Katja Department of Molecular Epidemiology, German Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany aut NATIONALLICENCE 700 1- Schulze Matthias Department of Molecular Epidemiology, German Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany aut NATIONALLICENCE 773 0- Current Diabetes Reports Current Science Inc 13/2(2013-04-01), 279-288 1534-4827 13:2<279 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer